Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
New York Medical College
Modality
antibody_drug_conjugate
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05253495CT.gov Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma | — | Recruiting | — | — | — |
NCT02581631CT.gov An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas | — | Completed | — | — | — |
NCT02408042CT.gov Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | — | Withdrawn | — | — | — |
NCT02280785CT.gov Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas | — | Completed | — | — | — |
NCT01703949CT.gov Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01777152CT.gov ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | — | Completed | — | — | — |
NCT01421667CT.gov A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01396070CT.gov Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | — | Completed | — | — | — |
NCT01026233CT.gov Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | — | Completed | — | — | — |
NCT01026415CT.gov Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | — | Completed | — | — | — |
Show 5 more trialsShow fewer
NCT00947856CT.gov A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study | — | Completed | — | — | — |
NCT00866047CT.gov A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma | — | Completed | — | — | — |
NCT00649584CT.gov A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | — | Terminated | — | — | — |
NCT00430846CT.gov Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | — | Completed | — | — | — |
NCT01196208CT.gov A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brentuximab Vedotin (this asset) | New York Medical College | P3 | BB · 65 |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Pegaspargase | Ciusss de L'Est de l'Île de Montréal | P4 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Prednisolone | Mwanasha Merrill, MD | P3 | BBB |
| Entecavir | Fudan University | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Rituximab | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Non-Hodgkin Lymphoma cohort
Other indications for Brentuximab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Anaplastic Large Cell Lymphoma | — | P3 | BBB · 72 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brentuximab Vedotin in Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brentuximab-vedotin-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →